[HTML][HTML] Clonal deletion of tumor-specific T cells by interferon-γ confers therapeutic resistance to combination immune checkpoint blockade
CCS Pai, JT Huang, X Lu, DM Simons, C Park… - Immunity, 2019 - cell.com
Resistance to checkpoint-blockade treatments is a challenge in the clinic. We found that
although treatment with combined anti-CTLA-4 and anti-PD-1 improved control of …
although treatment with combined anti-CTLA-4 and anti-PD-1 improved control of …
[HTML][HTML] Clonal Deletion of Tumor-Specific T Cells by Interferon-γ Confers Therapeutic Resistance to Combination Immune Checkpoint Blockade
CCS Pai, JT Huang, X Lu, DM Simons, C Park… - Immunity, 2019 - ncbi.nlm.nih.gov
Resistance to checkpoint-blockade treatments is a challenge in the clinic. We found that
although treatment with combined anti-CTLA-4 and anti-PD-1 improved control of …
although treatment with combined anti-CTLA-4 and anti-PD-1 improved control of …
Clonal Deletion of Tumor-Specific T Cells by Interferon-γ Confers Therapeutic Resistance to Combination Immune Checkpoint Blockade.
CS Pai, JT Huang, X Lu, DM Simons, C Park, A Chang… - Immunity, 2019 - europepmc.org
Resistance to checkpoint-blockade treatments is a challenge in the clinic. We found that
although treatment with combined anti-CTLA-4 and anti-PD-1 improved control of …
although treatment with combined anti-CTLA-4 and anti-PD-1 improved control of …
Clonal Deletion of Tumor-Specific T Cells by Interferon-γ Confers Therapeutic Resistance to Combination Immune Checkpoint Blockade
CCS Pai, JT Huang, X Lu, DM Simons… - …, 2019 - utsouthwestern.elsevierpure.com
Resistance to checkpoint-blockade treatments is a challenge in the clinic. We found that
although treatment with combined anti-CTLA-4 and anti-PD-1 improved control of …
although treatment with combined anti-CTLA-4 and anti-PD-1 improved control of …
Clonal Deletion of Tumor-Specific T Cells by Interferon-γ Confers Therapeutic Resistance to Combination Immune Checkpoint Blockade.
CCS Pai, JT Huang, X Lu, DM Simons, C Park… - Immunity, 2019 - escholarship.org
Resistance to checkpoint-blockade treatments is a challenge in the clinic. We found that
although treatment with combined anti-CTLA-4 and anti-PD-1 improved control of …
although treatment with combined anti-CTLA-4 and anti-PD-1 improved control of …
[HTML][HTML] Clonal Deletion of Tumor-Specific T Cells by Interferon-γ Confers Therapeutic Resistance to Combination Immune Checkpoint Blockade
CCS Pai, JT Huang, X Lu, DM Simons, C Park… - Immunity, 2019 - Elsevier
Resistance to checkpoint-blockade treatments is a challenge in the clinic. We found that
although treatment with combined anti-CTLA-4 and anti-PD-1 improved control of …
although treatment with combined anti-CTLA-4 and anti-PD-1 improved control of …
Clonal Deletion of Tumor-Specific T Cells by Interferon-γ Confers Therapeutic Resistance to Combination Immune Checkpoint Blockade
CCS Pai, JT Huang, X Lu, DM Simons, C Park… - …, 2019 - pubmed.ncbi.nlm.nih.gov
Resistance to checkpoint-blockade treatments is a challenge in the clinic. We found that
although treatment with combined anti-CTLA-4 and anti-PD-1 improved control of …
although treatment with combined anti-CTLA-4 and anti-PD-1 improved control of …
Clonal Deletion of Tumor-Specific T Cells by Interferon-γ Confers Therapeutic Resistance to Combination Immune Checkpoint Blockade.
CS Pai, JT Huang, X Lu, DM Simons, C Park, A Chang… - Immunity, 2019 - europepmc.org
Resistance to checkpoint-blockade treatments is a challenge in the clinic. We found that
although treatment with combined anti-CTLA-4 and anti-PD-1 improved control of …
although treatment with combined anti-CTLA-4 and anti-PD-1 improved control of …